Clinical Trial Update: A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JMT601 in adults with primary membranous nephropathy, sponsored by Shanghai JMT-Bio Inc., is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• JMT601

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Primary Membranous Nephropathy | Phase 2 | Status: NOT_YET_RECRUITING